Evidence map›Paper›PMID 36187353›Full record

ArticleFrontiers in molecular neuroscience2022

More than a marker: potential pathogenic functions of MAP2.

Rebecca A DeGiosio, Melanie J Grubisha, Matthew L MacDonald, Brandon C McKinney, Carlos J Camacho, Robert A Sweet

Abstract read
In one paragraph

Article in Frontiers in molecular neuroscience, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 99 papers.

0numbers the graph read from it
0cells of the map it votes in
99citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

99 citing papers in PubMed.

  1. Trial
  2. Article
  3. Human Neurotoxicity of Trichloroethylene: A Biomarker Approach.Journal of applied toxicology : JAT · 2026
    Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. A novel mouse model of rare neurodevelopmental disorder, TBCK Syndrome.bioRxiv : the preprint server for biology · 2026
    Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Insights Into the Antigenic Repertoire of Unclassified Synaptic Antibodies.Annals of clinical and translational neurology · 2026
    Article
  17. Article
  18. Article
  19. Article
  20. Article

39 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Rebecca A DeGiosioDepartment of Psychiatry, University of Pittsburgh, Pittsburgh, PA, United States.
Melanie J GrubishaDepartment of Psychiatry, University of Pittsburgh, Pittsburgh, PA, United States.
Matthew L MacDonaldDepartment of Psychiatry, University of Pittsburgh, Pittsburgh, PA, United States.
Brandon C McKinneyDepartment of Psychiatry, University of Pittsburgh, Pittsburgh, PA, United States.
Carlos J CamachoDepartment of Computational and Systems Biology, University of Pittsburgh, Pittsburgh, PA, United States.
Robert A SweetDepartment of Psychiatry, University of Pittsburgh, Pittsburgh, PA, United States.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Microtubule-associated protein 2 (MAP2) is the predominant cytoskeletal regulator within neuronal dendrites, abundant and specific enough to serve as a robust somatodendritic marker. It influences microtubule dynamics and microtubule/actin interactions to control neurite outgrowth and synaptic functions, similarly to the closely related MAP Tau. Though pathology of Tau has been well appreciated in the context of neurodegenerative disorders, the consequences of pathologically dysregulated MAP2 have been little explored, despite alterations in its immunoreactivity, expression, splicing and/or stability being observed in a variety of neurodegenerative and neuropsychiatric disorders including Huntington's disease, prion disease, schizophrenia, autism, major depression and bipolar disorder. Here we review the understood structure and functions of MAP2, including in neurite outgrowth, synaptic plasticity, and regulation of protein folding/transport. We also describe known and potential mechanisms by which MAP2 can be regulated

Indexed as

cytoskeletonMAP2neurodegenerationneurodevelopmentpsychiatric disorder

Identifiers

PMID36187353
PMCPMC9525131

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.